IPP Bureau
Alcon India launches Unity VCS/CS for vitreoretinal and cataract surgery
By IPP Bureau - September 09, 2025
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
Congruence gets $32 million financing to advance genetic obesity candidate drug
By IPP Bureau - September 09, 2025
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Biocytogen and Merck to advance antibody-conjugated lipid-based delivery solutions
By IPP Bureau - September 09, 2025
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Gilead Sciences breaks ground on new manufacturing and technical development site in US
By IPP Bureau - September 09, 2025
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
MRM Health raises €55 million Series B to advance microbiome-based biotherapeutic product pipeline
By IPP Bureau - September 09, 2025
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
FDA grants Fast Track Designation for Teva’s Emrusolmin
By IPP Bureau - September 09, 2025
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Argo Biopharma inks $5.2 billion deal with Novartis for novel molecules for cardiovascular diseases
By IPP Bureau - September 08, 2025
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
HealthEdge and UST HealthProof Merge to create AI-powered healthcare payer technology
By IPP Bureau - September 08, 2025
Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
Zydus Lifesciences appoints Nitin Parekh as President (Special Projects)
By IPP Bureau - September 08, 2025
He has been associated with the Zydus Group since 2009
Strides partners with Kenox to expand nasal spray portfolio for US market
By IPP Bureau - September 08, 2025
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
USFDA conducts product specific pre-approval inspection at Lupin’s Aurangabad facility
By IPP Bureau - September 08, 2025
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
FDA approves sBLA for Takeda's Vonvendi for Von Willebrand disease
By IPP Bureau - September 08, 2025
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Aptar Pharma partners with Dianosic to advance ARIS platform for treatment of chronic allergic rhinitis and rhinosinusitis
By IPP Bureau - September 08, 2025
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC
By IPP Bureau - September 06, 2025
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Poly Medicure to acquire 90% stake in PendraCare Group for € 18.3 million
By IPP Bureau - September 06, 2025
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
